helicobacter pylori
Conditions
Interventions
10-day vonoprazan-amoxicillin dual therapy group:vonoprazan 20mg bid + amoxicillin 1000mg tid
14-day high-dose esomeprazole-amoxicillin dual therapy group:esomeprazole 20mg bid + amoxicillin 750mg qid
Sponsors
Affiliated Hospital of Yangzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Adult patients, aged 18-70 years, no gender limit; 2. H. pylori-infected patients diagnosed with 13C-Urea breath test (UBT) or 14C-UBT; 3. Did not receive standardized H. pylori eradication therapy; 4. Participate in the study voluntarily and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who are allergic to the drug under study (amoxicillin, Vonorazone or esomeprazole); 2. Used antibiotics and bismuth in the last 4 weeks, or took PPI in the last 2 weeks; 3. Patients with serious heart, lung, liver, kidney and other diseases and low immunity; 4. Patients with acute upper gastrointestinal bleeding, gastrointestinal malignant tumor, Zhuo-Ai syndrome, gastric cancer surgery history; 5. During pregnancy or lactation; 6. Those who suffer from mental illness or cognitive impairment and cannot cooperate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events;Compliance;Intestinal microbiota;Detection of drug resistance genes in Helicobacter pylori; | — |
Countries
China
Contacts
Public ContactDing Yanbing
Department of Gastroenterology, Affiliated Hospital of Yangzhou University
Outcome results
None listed